Japanese Encephalitis

10
Pipeline Programs
1
Companies
15
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
4
0
5
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
6100%
+ 5 programs with unclassified modality

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Sanofi
SanofiPARIS, France
11 programs
4
5
1
IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccinePhase 4Vaccine1 trial
ChimeriVax™-JEPhase 31 trial
IMOJEVPhase 34 trials
JE-CV VaccinePhase 3Vaccine1 trial
Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virusPhase 31 trial
+6 more programs
Active Trials
NCT02526550Completed50Est. Jul 2014
NCT02602652Completed50Est. Jul 2015
NCT00441259Completed96Est. Dec 2011
+12 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Sanofia live attenuated chimeric JE vaccine
SanofiIMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine
SanofiIMOJEV
SanofiIMOJEV
SanofiIMOJEV
SanofiJE-CV Vaccine
SanofiJapanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus
SanofiJapanese encephalitis vaccine
SanofiChimeriVax™-JE
SanofiJapanese encephalitis vaccine
SanofiChimeriVax™-JE
SanofiChimeriVax™-JE vaccine
SanofiLive attenuated Japanese encephalitis virus; Yellow fever virus
SanofiIMOJEV
Sanofia live attenuated chimeric JE vaccine

Clinical Trials (15)

Total enrollment: 14,373 patients across 15 trials

NCT02526550Sanofia live attenuated chimeric JE vaccine

Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX

Start: Jun 2014Est. completion: Jul 201450 patients
Phase 4Completed
NCT01981967SanofiIMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine

Post-licensure Safety Study of IMOJEV® in Thailand

Start: Nov 2013Est. completion: Oct 201510,000 patients
Phase 4Completed
NCT02492165SanofiIMOJEV

Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects

Start: Jun 2015Est. completion: Jun 2016250 patients
Phase 3Completed
NCT01900444SanofiIMOJEV

Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea

Start: Jul 2013Est. completion: Mar 2014119 patients
Phase 3Completed
NCT01396512SanofiIMOJEV

Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers

Start: Jul 2011Est. completion: Jun 2013274 patients
Phase 3Completed
NCT01190228SanofiJE-CV Vaccine

Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV

Start: Aug 2010Est. completion: Oct 2015454 patients
Phase 3Completed
NCT01188343SanofiJapanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus

Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers

Start: Aug 2010Est. completion: Dec 2012542 patients
Phase 3Completed
NCT00735644SanofiJapanese encephalitis vaccine

Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines

Start: Aug 2008Est. completion: Aug 20091,200 patients
Phase 3Completed
NCT00314145SanofiChimeriVax™-JE

A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX

Start: Nov 2005Est. completion: Nov 2006820 patients
Phase 3Completed
NCT00621764SanofiJapanese encephalitis vaccine

Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children

Start: Mar 2008Est. completion: May 2013300 patients
Phase 2Completed
NCT00441259SanofiChimeriVax™-JE

Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age

Start: Jan 2007Est. completion: Dec 201196 patients
Phase 2Completed
NCT00319592SanofiChimeriVax™-JE vaccine

A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX

Start: May 2005Est. completion: Sep 200660 patients
Phase 2Completed
NCT00982137SanofiLive attenuated Japanese encephalitis virus; Yellow fever virus

Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)

Start: Jul 2004Est. completion: Mar 2007108 patients
Phase 2Completed
NCT02933710SanofiIMOJEV

Postmarketing Surveillance Study for IMOJEV® in Republic of Korea

Start: Jul 2016Est. completion: Oct 201850 patients
N/ACompleted
NCT02602652Sanofia live attenuated chimeric JE vaccine

Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine

Start: Dec 2013Est. completion: Jul 201550 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs — potential near-term approvals
Vaccine is the dominant modality (100% of programs)
1 companies competing in this space